Table 1.
Status, n (%) | Vismodegib 150 mg/day + pirfenidone ≤ 2403 mg/day (N = 21) |
---|---|
Completed 24-week treatment phase | 15 (71.4) |
Completed safety follow-up | 15 (71.4) |
Discontinued 24-week treatment phase | 6 (28.6) |
Adverse event | 4 (19.0) |
Withdrawal by patient | 1 (4.8) |
Other | 1 (4.8) |